STOCK TITAN

Unity Biotechnology Inc - UBX STOCK NEWS

Welcome to our dedicated news page for Unity Biotechnology (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Unity Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Unity Biotechnology's position in the market.

Rhea-AI Summary
UNITY Biotechnology, Inc. announces two poster presentations at the ARVO 2024 Annual Meeting focusing on senolytic candidates for patients with DME and wet AMD, showcasing potential benefits in disease management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
-
Rhea-AI Summary
UNITY Biotechnology extends Phase 2b ASPIRE Clinical Study to assess UBX1325 in DME, aiming for increased durability and statistical power. The study compares UBX1325 to aflibercept in diabetic macular edema patients, targeting senescent cells for potential vision improvement. UNITY plans to release topline results in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
-
Rhea-AI Summary
UNITY Biotechnology, Inc. reported its financial results for the fourth quarter and full year 2023, highlighting progress in their Phase 2b ASPIRE study for diabetic macular edema. The company's CEO, Anirvan Ghosh, expressed optimism about the positive BEHOLD data and the potential of UBX1325 (foselutoclax) compared to aflibercept.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
Rhea-AI Summary
UNITY Biotechnology, Inc. (UBX) announced new research in Nature Medicine supporting the clearance of senescent cells in the retina as a therapeutic approach for diabetic macular edema. The study shows potential long-term improvements in vision and retinal structure stabilization in patients with advanced disease. The BCL-xL inhibitor UBX1325 demonstrated improvements in visual acuity and reduced anti-VEGF treatment burden in a Phase 2 study. UNITY is enrolling patients for a Phase 2b clinical trial with 16-week results expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
none
-
Rhea-AI Summary
UNITY Biotechnology, Inc. (UBX) announced the dosing of the first patients in the Phase 2 ASPIRE study of UBX1325, a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema. The study is expected to share initial results in the fourth quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
-
Rhea-AI Summary
UNITY Biotechnology, Inc. (UBX) Reports Positive Efficacy Data for UBX1325 in Patients with Diabetic Macular Edema
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
Rhea-AI Summary
UNITY Biotechnology, Inc. (UBX) announces the immediate exercise of warrants to purchase 2,143,000 shares of common stock at a reduced price of $2.045 per share, expecting gross proceeds of approximately $4.38 million. The exercise price was reduced from $8.50 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
Rhea-AI Summary
UNITY Biotechnology announces positive results from Phase 2 ENVISION study of UBX1325 in patients with wet AMD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
Unity Biotechnology Inc

Nasdaq:UBX

UBX Rankings

UBX Stock Data

25.51M
12.64M
1.25%
28.33%
1.83%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Brisbane

About UBX

unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.